LYMPHOMA, NON-HODGKIN

This study tested an experimental drug called mosunetuzumab, given alone or with another drug (atezolizumab), in 713 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had come back or stopped responding to prior treatments. The goal was to find the safe…

This early-phase study tested an experimental drug called JNJ-75348780 in 147 people with two types of blood cancer (non-Hodgkin lymphoma and chronic lymphocytic leukemia) that had returned or stopped responding to other treatments. The drug is designed to help the immune system …

This early-stage study tested a new drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. LP-118 works by blocking certain proteins that…

This study looked at a new way to do bone marrow transplants for people with blood cancers like leukemia and lymphoma who don't have a perfectly matched donor. Instead of using a standard drug after transplant, doctors tested a different drug called bendamustine to see if it coul…

This study tested an oral drug called LOXO-305 in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma whose cancer had returned or not responded to prior treatments. The main goal was to see how many patients had their tumors s…

This early-phase study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 5 children and young adults whose Hodgkin or non-Hodgkin lymphoma had come back or stopped responding to standard treatments. The main goals were to check safety, find the right d…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and shrinks tumors. Some participants received just one of the drugs for comparison. The study…

This study tested whether adding the drug copanlisib to standard rituximab therapy helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. About 458 adults who had already received at least one prior treatment took part. T…

This study looked at genetic information from over 1,300 stored samples of lymphoma, leukemia, and multiple myeloma to find new ways to classify these cancers. Researchers wanted to understand why some patients respond well to treatment while others do not. No new patients were r…

This study looked at how healthy men absorb, break down, and eliminate a drug called DZD8586, which is being developed for non-Hodgkin lymphoma. Six healthy male volunteers took a single dose with a tiny radioactive marker so scientists could track it in blood, urine, and stool. …

This study looked back at 30 people with HIV who were treated with CAR T-cell therapy for certain blood cancers like lymphoma or leukemia. Researchers collected standard medical data to see how often side effects occurred and how the immune system changed over time. The goal was …